327 related articles for article (PubMed ID: 30329034)
1. Vedolizumab in Refractory Microscopic Colitis: An International Case Series.
Rivière P; Münch A; Michetti P; Chande N; de Hertogh G; Schoeters P; Ferrante M; Vermeire S; Van Assche G
J Crohns Colitis; 2019 Mar; 13(3):337-340. PubMed ID: 30329034
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of anti-TNF therapies in refractory severe microscopic colitis.
Esteve M; Mahadevan U; Sainz E; Rodriguez E; Salas A; Fernández-Bañares F
J Crohns Colitis; 2011 Dec; 5(6):612-8. PubMed ID: 22115383
[TBL] [Abstract][Full Text] [Related]
3. Treatment of microscopic colitis: the role of budesonide and new alternatives for refractory patients.
Rojo E; Casanova MJ; Gisbert JP
Rev Esp Enferm Dig; 2020 Jan; 112(1):53-58. PubMed ID: 31880163
[TBL] [Abstract][Full Text] [Related]
4. Systematic review: are lymphocytic colitis and collagenous colitis two subtypes of the same disease - microscopic colitis?
Rasmussen MA; Munck LK
Aliment Pharmacol Ther; 2012 Jul; 36(2):79-90. PubMed ID: 22670660
[TBL] [Abstract][Full Text] [Related]
5. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.
Miehlke S; Madisch A; Kupcinskas L; Petrauskas D; Böhm G; Marks HJ; Neumeyer M; Nathan T; Fernández-Bañares F; Greinwald R; Mohrbacher R; Vieth M; Bonderup OK;
Gastroenterology; 2014 May; 146(5):1222-30.e1-2. PubMed ID: 24440672
[TBL] [Abstract][Full Text] [Related]
6. Microscopic colitis: an unfamiliar but treatable disease.
van der Wouden EJ; Karrenbeld A; Kleibeuker JH; Dijkstra G
Neth J Med; 2009 Feb; 67(2):41-5. PubMed ID: 19299845
[TBL] [Abstract][Full Text] [Related]
7. Lymphocytic colitis and collagenous colitis: a review of clinicopathologic features and immunologic abnormalities.
Mahajan D; Goldblum JR; Xiao SY; Shen B; Liu X
Adv Anat Pathol; 2012 Jan; 19(1):28-38. PubMed ID: 22156832
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with long-term clinical outcome in microscopic colitis.
Miyatani Y; Komaki Y; Komaki F; Micic D; Keyashian K; Sakuraba A
Ann Med; 2024 Dec; 56(1):2365989. PubMed ID: 38900021
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and patterns and predictors of response to therapy in collagenous and lymphocytic colitis.
Colussi D; Salari B; Stewart KO; Lauwers GY; Richter JR; Chan AT; Ricciardiello L; Khalili H
Scand J Gastroenterol; 2015; 50(11):1382-8. PubMed ID: 25997458
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab in budesonide and methotrexate refractory collagenous colitis.
Münch A; Ignatova S; Ström M
Scand J Gastroenterol; 2012 Jan; 47(1):59-63. PubMed ID: 22149977
[TBL] [Abstract][Full Text] [Related]
11. Incidence, Clinical Presentation, and Associated Factors of Microscopic Colitis in Northern France: A Population-Based Study.
Fumery M; Kohut M; Gower-Rousseau C; Duhamel A; Brazier F; Thelu F; Nagorniewicz F; Lamarche F; Nguyen-Khac E; Sabbagh C; Loreau J; Colombel JF; Savoye G; Chatelain D; Dupas JL; ;
Dig Dis Sci; 2017 Jun; 62(6):1571-1579. PubMed ID: 27659673
[TBL] [Abstract][Full Text] [Related]
12. Biologic Therapy for Budesonide-refractory, -dependent or -intolerant Microscopic Colitis: a Multicentre Cohort Study from the GETAID.
Boivineau G; Zallot C; Zerbib F; Plastaras L; Amiot A; Boivineau L; Koch S; Peyrin-Biroulet L; Vuitton L
J Crohns Colitis; 2022 Dec; 16(12):1816-1824. PubMed ID: 35793161
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.
Davis R; McParland P; Dodd S; Storey D; Probert C; Collins P; Skouras T; Steel A; Derbyshire E; Dibb M; Subramanian S
Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):661-667. PubMed ID: 30855421
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab for induction and maintenance of remission in ulcerative colitis.
Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG
Cochrane Database Syst Rev; 2014 Aug; (8):CD007571. PubMed ID: 25105240
[TBL] [Abstract][Full Text] [Related]
15. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab as a Novel Treatment for Refractory Collagenous Colitis: A Case Report.
Cushing KC; Mino-Kenudson M; Garber J; Lochhead P; Khalili H
Am J Gastroenterol; 2018 Apr; 113(4):632-633. PubMed ID: 29610507
[No Abstract] [Full Text] [Related]
17. Immune modulator therapy for microscopic colitis in a case series of 73 patients.
Cotter TG; Kamboj AK; Hicks SB; Tremaine WJ; Loftus EV; Pardi DS
Aliment Pharmacol Ther; 2017 Jul; 46(2):169-174. PubMed ID: 28488312
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
20. Single-centre experience with anti-tumour necrosis factor treatment in budesonide-refractory microscopic colitis patients.
Daferera N; Hjortswang H; Ignatova S; Münch A
United European Gastroenterol J; 2019 Nov; 7(9):1234-1240. PubMed ID: 31700636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
